Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
Careers | Find us | Contact us
Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients
Wellcome Genome Campus,
Hinxton, Cambridgeshire,
CB10 1SA. UK
+44 (0)1223 834244


Wellcome Genome Campus,
Hinxton, Cambridgeshire, CB10 1SA. UK
+44 (0)1223 834244

